Cargando…
Safety and tolerability evaluation after repeated intravitreal injections of a humanized anti-VEGF-A monoclonal antibody (PRO-169) versus ranibizumab in New Zealand white rabbits
BACKGROUND: To evaluate the retinal toxicity after repeated intravitreal injections of a humanized anti-VEGF-A monoclonal antibody (PRO-169) versus ranibizumab in New Zealand white (NZW) rabbit eyes. METHODS: NZW rabbits were injected intravitreally with PRO-169 (n = 12), 1.25 mg/0.05 ml or ranibizu...
Autores principales: | Baiza-Durán, Leopoldo, Sánchez-Ríos, Alejandra, González-Barón, Joel, Olvera-Montaño, Oscar, Correa-Gallegos, Elba, Navarro-Sánchez, Andrea, Muñoz-Villegas, Patricia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7389522/ https://www.ncbi.nlm.nih.gov/pubmed/32742719 http://dx.doi.org/10.1186/s40942-020-00235-y |
Ejemplares similares
-
Pharmacokinetics and Safety of an Intravitreal Humanized Anti-VEGF-A Monoclonal Antibody (PRO-169), a Biosimilar Candidate to Bevacizumab
por: Muñoz-Villegas, Patricia, et al.
Publicado: (2021) -
Validation of a preclinical dry eye model in New Zealand white rabbits during and following topical instillation of 1% ophthalmic atropine sulfate
por: Sánchez‐Ríos, Alejandra, et al.
Publicado: (2022) -
Efficacy and Safety of an Ophthalmic DMPC-Based Nanoemulsion in Patients with Dry Eye Disease: A Phase I/II Randomized Clinical Trial
por: Baiza-Durán, Leopoldo M., et al.
Publicado: (2023) -
Reexamining Ophthalmic Drugs, Safety and Tolerability in Phase 1 Clinical Trials
por: Muñoz-Villegas, Patricia, et al.
Publicado: (2021) -
Bioavailability of generic 0.05% difluprednate emulsion in the aqueous humor, cornea, and conjunctiva of New Zealand rabbits after a single dose compared with commercial difluprednate
por: Mercado-Sesma, Arieh, et al.
Publicado: (2017)